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Abstract
© 2017  Malisheni,  Khaiboullina,  Rizvanov,  Takah,  Murewanhema  and  Bates.  Background:
Dengue hemorrhagic fever is the leading cause of hospitalization and death in children living in
Asia and Latin America. There is an urgent need for an effective and safe dengue vaccine to
reduce morbidity and mortality in this high-risk population given the lack of dengue specific
treatment at present. This review aims to determine the efficacy, safety, and immunogenicity of
CYD-TDV vaccine in children. Methods: This is a systematic review including meta-analysis of
randomized controlled clinical trial data from Embase, Medline, the Cochrane Library, Web of
Science, and ClinicalTrials.gov. Studies that assessed CYD-TDV vaccine efficacy [(1 - RR)*100],
safety (RR), and immunogenicity (weighted mean difference) in children were included in this
study.  Random effects  model  was  employed  to  analyze  patient-level  data  extracted  from
primary studies.  Results:  The overall  efficacy of  CYD-TDV vaccine was 54% (40-64),  while
serotype-specific efficacy was 77% (66-85) for DENV4, 75% (65-82) for DENV3, 50% (36-61) for
DENV1, and 34% (14-49) for DENV 2 . 15% (-174-74) vaccine efficacy was obtained for the
unknown serotype. Meta-analysis of included studies with longer follow-up time (25 months)
revealed that CYD-TDV vaccine significantly increased the risk of injection site reactions (RR =
1.1:  1.04-1.17;  p-value = 0.001).  Immunogenicity  (expressed as geometric  mean titers)  in
descending order was 439.7 (331.7-547.7), 323 (247 - 398.7), 144.1 (117.9-170.2), and 105
(88.7-122.8)  for  DENV3,  DENV 2  ,  DENV1,  and  DENV4,  respectively.  Conclusion:  CYD-TDV
vaccine is effective and immunogenic in children overall. Reduced efficacy of CYD-TDV vaccine
against DENV 2 notoriously known for causing severe dengue infection and dengue outbreaks
cause for serious concern. Post hoc meta-analysis of long-term follow-up data (≥25 months)
from children previously vaccinated with CYD-TDV vaccine is needed to make a conclusion
regarding CYD-TDV vaccine safety in children. However, CYD-TDV vaccine should be considered
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